Direct-to-Biology (D2B) has emerged as a powerful method to find hit compounds and build Structure Activity Relationships (SAR) for drug discovery programs. During this webinar, we will cover the concept of D2B and how and when it can be applied to drug-discovery programs. A case study will be presented demonstrating the potential of this approach.

Agenda:
14.00 – 14.05 – Introduction from One Nucleus and Domainex
14.05 – 14.45 – Presentation from Joe Mason, Associate Principal Scientist and Nick Bland, Group Leader, Domainex
14.45 – 15.00 – Q&A and Close

Registration
This webinar is free to attend.